- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04348344
Study on the Prevention and Control System of Chronic Airway Diseases
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
First of all, the investigators need to obtain detailed history records, including cardio pulmonary vascular history, related complications, treatment history and other high-risk factors. After careful review, the investigators need to determine whether the patient is suitable to participate in the pulmonary rehabilitation plan. The investigators need to pay special attention to diseases that may affect the patient's performance, including special cardiovascular diseases, skeletal muscle and nervous system.
Functional evaluation: pulmonary function test, exercise cardiopulmonary function evaluation (6-minute walking test), grip strength test, psychological state evaluation ( Generalized Anxiety Disorder 7-item (GAD-7), Patient Health Questionnaire 9-item (phq-9)), nutrition screening and evaluation and others (general examination such as height, weight, BMI, waist and hip circumference, WHR, blood pressure, heart rate and blood biochemical examination; quality of life evaluation; other related individual evaluation Estimation includes smoking and sleep).
Acute exacerbation:
The exercise prescription of "hospitalization + home rehabilitation" was adopted, which mainly combined aerobic endurance training, intermittent strength training and inspiratory muscle training, as follows:
Aerobic exercise: 4 times / week, 30min / time, fast walking or power cycling Strength training: unarmed or instrument, 4 times / week, 3 groups / time, 10-12 times / group Breath training: ① breath Trainer: once a day, 20-30min a time
② Abdominal breathing training: 1-2 times / day, 10min / time
- Stable patients:
Using the "home-based rehabilitation" exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training, as follows:
Aerobic exercise: 2-3 times / week, 30min / time, walk quickly Strength training: elastic band, 2-3 times / week, 3 groups / time, 10-12 times / group Breathing training: ① breathing exercise apparatus, 1-2 times / day, 10min / time
② Abdominal breathing training, 1-2 times / day, 10min / time
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ting Yang, MD
- Phone Number: 13651380809
- Email: dryangting@qq.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- It meets the diagnostic criteria of global initiative for chronic obstructive pulmonary disease (gold 2017 Edition), is in a stable period of disease or meets the diagnostic criteria of guidelines for the prevention and treatment of bronchial asthma (GINA 2016 Edition)
- Have lived in the local area for more than 2 consecutive years, and there is no plan to go out for more than half a year in succession during the survey period
- No smoking history or no smoking for half a year or more
- 40-75 years old
Exclusion Criteria:
- Patients with history of chronic diseases, such as serious cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, epilepsy and other nervous system diseases, mental diseases, psychiatric diseases, active pulmonary tuberculosis, tumor, anti tuberculosis treatment or combined influence information collection
- Patients who have undergone thoracic, abdominal and ophthalmic operations in the past 3 months
- Pregnant and lactating women
- Did not sign informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: intervention group
health education of pulmonary rehabilitation pulmonary rehabilitation including aerobic exercise,strength training and breath training. Patients in stable stages using the "home-based rehabilitation" exercise prescription, taking home exercise, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training, intermittent strength training and inspiratory muscle training. |
Patients receive health education of pulmonary rehabilitation, using the "home-based rehabilitation" exercise prescription, taking home exercise as the main form, using the sports bracelet and special respiratory rehabilitation app software, the home management system integrating home rehabilitation training, detection and feedback is mainly adopted, which is a combination of aerobic endurance training: walking, intermittent strength training: elastic band and inspiratory muscle training:apparatus, abdominal breathing training.
|
NO_INTERVENTION: control group
health education of pulmonary rehabilitation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline 6-minute Walking Distance at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
walking distance in 6-minute walking test
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Times of acute exacerbation
Time Frame: through study completion, an average of 1 year
|
times of acute exacerbation in the period of one year
|
through study completion, an average of 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time from the beginning of follow-up to the first acute exacerbation and the duration of the first acute exacerbation
Time Frame: 9 months
|
Time from the beginning of follow-up to the first acute exacerbation and the duration of the first acute exacerbation
|
9 months
|
Change from Baseline Fractional exhaled Nitric Oxide (FeNO) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
changes of Fractional exhaled Nitric Oxide (FeNO)
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Eosinophil Count in Sputum at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Eosinophil Count
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Inflammatory Factors in sputum at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
inflammatory factors in sputum
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline modified Medical Research Council dyspnea (mMRC) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
the minimum values is 0 and maximum values is 4, the higher scores mean a worse outcome.
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline COPD assessment test (CAT) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
the minimum values is 0 and maximum values is 40, the higher scores mean a worse outcome.
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline St George's questionnaire (SGRQ) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
the minimum values is 0 and maximum values is 100, the higher scores mean a worse outcome.
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Patient Health Questionnaire 9-item (PHQ-9) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
the minimum values is 0 and maximum values is 27, the higher scores mean a worse outcome.
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Generalized Anxiety Disorder 7-item (GAD-7) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
the minimum values is 0 and maximum values is 21, the higher scores mean a worse outcome.
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Pittsburgh Sleep Quality Index (PSQI) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
the minimum values is 0 and maximum values is 21, the higher scores mean a worse outcome.
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Pulmonary Function of FEV1 at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
FEV1
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Pulmonary Function of FVC at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
FVC
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Pulmonary Function of FEV1/FVC at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
FEV1/FVC
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from Baseline Body Mass Index (BMI) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
weight and height will be combined to report BMI in kg/m^2
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Weight in Kilograms at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
weight in kilograms
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Baseline Height in Meters at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
height in meters
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Waist Circumference in Centimeters at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
waist circumference in centimeters
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Hip Circumference in Centimeters at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
hip circumference in centimeters
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Change from Waist-Hip Ratio (WHR) at 4, 8, 12 weeks, 6 months and 12 months
Time Frame: baseline and 4, 8, 12 weeks, 6 months and 12 months
|
hip and waist circumference in centimeters will be combined to report WHR
|
baseline and 4, 8, 12 weeks, 6 months and 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Ting Yang, MD, China-Japan Friendship Hospital
Publications and helpful links
General Publications
- Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, Huang K, Yao W, Sun T, Shan G, Yang T, Lin Y, Wu S, Zhu J, Wang R, Shi Z, Zhao J, Ye X, Song Y, Wang Q, Zhou Y, Ding L, Yang T, Chen Y, Guo Y, Xiao F, Lu Y, Peng X, Zhang B, Xiao D, Chen CS, Wang Z, Zhang H, Bu X, Zhang X, An L, Zhang S, Cao Z, Zhan Q, Yang Y, Cao B, Dai H, Liang L, He J; China Pulmonary Health Study Group. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717. doi: 10.1016/S0140-6736(18)30841-9. Epub 2018 Apr 9.
- Alison JA, McKeough ZJ, Johnston K, McNamara RJ, Spencer LM, Jenkins SC, Hill CJ, McDonald VM, Frith P, Cafarella P, Brooke M, Cameron-Tucker HL, Candy S, Cecins N, Chan AS, Dale MT, Dowman LM, Granger C, Halloran S, Jung P, Lee AL, Leung R, Matulick T, Osadnik C, Roberts M, Walsh J, Wootton S, Holland AE; Lung Foundation Australia and the Thoracic Society of Australia and New Zealand. Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology. 2017 May;22(4):800-819. doi: 10.1111/resp.13025. Epub 2017 Mar 24.
- Spruit MA, Singh SJ, Garvey C, ZuWallack R, Nici L, Rochester C, Hill K, Holland AE, Lareau SC, Man WD, Pitta F, Sewell L, Raskin J, Bourbeau J, Crouch R, Franssen FM, Casaburi R, Vercoulen JH, Vogiatzis I, Gosselink R, Clini EM, Effing TW, Maltais F, van der Palen J, Troosters T, Janssen DJ, Collins E, Garcia-Aymerich J, Brooks D, Fahy BF, Puhan MA, Hoogendoorn M, Garrod R, Schols AM, Carlin B, Benzo R, Meek P, Morgan M, Rutten-van Molken MP, Ries AL, Make B, Goldstein RS, Dowson CA, Brozek JL, Donner CF, Wouters EF; ATS/ERS Task Force on Pulmonary Rehabilitation. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013 Oct 15;188(8):e13-64. doi: 10.1164/rccm.201309-1634ST. Erratum In: Am J Respir Crit Care Med. 2014 Jun 15;189(12):1570.
- Loeckx M, Rabinovich RA, Demeyer H, Louvaris Z, Tanner R, Rubio N, Frei A, De Jong C, Gimeno-Santos E, Rodrigues FM, Buttery SC, Hopkinson NS, Busching G, Strassmann A, Serra I, Vogiatzis I, Garcia-Aymerich J, Polkey MI, Troosters T. Smartphone-Based Physical Activity Telecoaching in Chronic Obstructive Pulmonary Disease: Mixed-Methods Study on Patient Experiences and Lessons for Implementation. JMIR Mhealth Uhealth. 2018 Dec 21;6(12):e200. doi: 10.2196/mhealth.9774.
- Storer TW. Exercise in chronic pulmonary disease: resistance exercise prescription. Med Sci Sports Exerc. 2001 Jul;33(7 Suppl):S680-92. doi: 10.1097/00005768-200107001-00006.
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-161-K110
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on pulmonary rehabilitation
-
Faculty of Medicine, SousseCompletedChronic Obstructive Pulmonary DiseaseTunisia
-
Universidade Federal de Santa MariaCompletedChronic Obstructive Pulmonary DiseaseBrazil
-
Istanbul Medipol University HospitalRecruitingLung Diseases | Bronchiectasis | Lung Diseases, Interstitial | Pulmonary RehabilitationTurkey
-
La Trobe UniversityMonash University; The Alfred; Austin HealthCompletedChronic Obstructive Pulmonary DiseaseAustralia
-
Aveiro UniversityCentro Hospitalar do Baixo VougaRecruitingChronic Obstructive Pulmonary Disease | Interstitial Lung DiseasePortugal
-
National Cheng-Kung University HospitalCompletedTelerehabilitation | Pulmonary Rehabilitation | Compliance, Patient | COPD | Cardiopulmonary Exercise TestTaiwan
-
Istanbul Medipol University HospitalCompletedEmphysema | Bronchoscopic Lung Volume Reduction | Hospital-based Pulmonary Rehabilitation | Home-based Pulmonary RehabilitationTurkey
-
Hospital Clinic of BarcelonaSociedad Española de Neumología y Cirugía TorácicaUnknownNon-cystic Fibrosis Bronchiectasis
-
University of MaltaCompletedInterstitial Lung DiseaseMalta
-
Copenhagen University Hospital, HvidovreCopenhagen University Hospital Bispebjerg-Frederiksberg; Copenhagen University... and other collaboratorsRecruiting